000 01612 a2200469 4500
005 20250514235404.0
264 0 _c20060818
008 200608s 0 0 eng d
022 _a0770-3198
024 7 _a10.1007/s10067-005-1156-z
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aSamarkos, M
245 0 0 _aClinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome.
_h[electronic resource]
260 _bClinical rheumatology
_cMar 2006
300 _a199-204 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntibodies, Anticardiolipin
_xblood
650 0 4 _aAntiphospholipid Syndrome
_ximmunology
650 0 4 _aAutoantibodies
_xblood
650 0 4 _aEnzyme-Linked Immunosorbent Assay
650 0 4 _aEthnicity
650 0 4 _aFemale
650 0 4 _aGlycoproteins
_ximmunology
650 0 4 _aHumans
650 0 4 _aImmunoglobulin A
_xanalysis
650 0 4 _aImmunoglobulin G
_xanalysis
650 0 4 _aImmunoglobulin M
_xanalysis
650 0 4 _aLupus Erythematosus, Systemic
_ximmunology
650 0 4 _aMale
650 0 4 _aMiddle Aged
650 0 4 _aRetrospective Studies
650 0 4 _aSensitivity and Specificity
650 0 4 _abeta 2-Glycoprotein I
700 1 _aDavies, K A
700 1 _aGordon, C
700 1 _aLoizou, S
773 0 _tClinical rheumatology
_gvol. 25
_gno. 2
_gp. 199-204
856 4 0 _uhttps://doi.org/10.1007/s10067-005-1156-z
_zAvailable from publisher's website
999 _c15729908
_d15729908